[Form 4] Medpace Holdings, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Medpace Holdings, Inc. (MEDP) reported an insider transaction by Director Fred B. Davenport, Jr. on 10/30/2025. He exercised a stock option to acquire 6,472 shares of common stock at an exercise price of $54.99 (code M), then sold 5,972 shares at a weighted average price of $581.88 in trades ranging from $580.53 to $585.26 (code S).

Following these transactions, he directly held 3,498 shares of MEDP common stock and indirectly held 2,000 shares through a trust. The exercised option covered 6,472 underlying shares and had fully vested on May 14, 2020, with an option expiration of May 17, 2026. After the exercise, 0 derivative securities remained beneficially owned.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DAVENPORT FRED B JR

(Last) (First) (Middle)

C/O MEDPACE HOLDINGS, INC.

5375 MEDPACE WAY

(Street)

CINCINNATI OH 45227

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Medpace Holdings, Inc. [ MEDP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/30/2025		M		6,472	A	$54.99	9,470	D
Common Stock	10/30/2025		S		5,972	D	$581.88(1)	3,498	D
Common Stock								2,000	I	By Trust(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$54.99	10/30/2025		M			6,472	(3)	05/17/2026	Common Stock	6,472	$0	0	D

Explanation of Responses:

1. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $580.53 to $585.26. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

2. Owned by trust for the benefit of the Reporting Person.

3. The option vested in full on May 14, 2020.

Remarks:

	/s/ Stephen P. Ewald, Attorney-in-Fact for Fred B. Davenport, Jr.	11/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did MEDP director Fred B. Davenport, Jr. report on Form 4?

He exercised options for 6,472 shares at $54.99 and sold 5,972 shares at a weighted average of $581.88 on 10/30/2025.

How many MEDP shares does the reporting person hold after the transactions?

He holds 3,498 shares directly and 2,000 shares indirectly via a trust.

What price range were the MEDP share sales executed at?

Multiple trades occurred between $580.53 and $585.26.

What were the terms of the exercised MEDP stock option?

It covered 6,472 shares at $54.99, vested on May 14, 2020, and expires on May 17, 2026.

Were any derivative securities left after the MEDP option exercise?

No. The Form 4 shows 0 derivative securities beneficially owned after the exercise.